Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.24 USD
+0.06 (5.08%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $1.23 -0.01 (-0.81%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.24 USD
+0.06 (5.08%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $1.23 -0.01 (-0.81%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Zacks News
Nektar Starts Phase I/II Combo for Advanced Solid Tumors
by Zacks Equity Research
Nektar (NKTR) initiates dosing in a phase I/II study, evaluating the combination of its two novel immuno-oncology agents, NKTR-262 and NKTR-214, on patients with advanced solid tumors.
Nektar (NKTR) Q4 Loss Narrower Than Expected, Sales Soar Y/Y
by Zacks Equity Research
Nektar (NKTR) reports narrower-than-expected loss in Q4. Revenues substantially rise year over year owing to massive increase in license and collaboration fees.
Why Nektar (NKTR) Might Surprise This Earnings Season
by Zacks Equity Research
Nektar (NKTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock (Revised)
by Zacks Equity Research
Nektar (NKTR) inks a joint global collaboration deal with Bristol-Myers to develop and commercialize its cancer candidate, NKTR-214, in combination with the other party's Opdivo and Opdivo plus Yervoy.
Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock
by Zacks Equity Research
Nektar (NKTR) inks a joint global collaboration deal with Bristol-Myers to develop and commercialize its cancer candidate, NKTR-214, combined with the other party's Opdivo and Opdivo plus Yervoy.
Nektar (NKTR) Surges: Stock Moves 11% Higher
by Zacks Equity Research
Nektar (NKTR) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
5 Best-Performing Stocks of the Top ETF of January
by Sweta Killa
Inside the top performing stocks of the top biotech ETF of January.
Here's Why Nektar Stock Skyrocketed Almost 500% in a Year
by Zacks Equity Research
Nektar's (NKTR) shares soar in a year's time on a robust pipeline including several study initiations, positive readouts and strategic collaborations.
Nektar Boasts Strong Pipeline, Competition Remains a Woe
by Zacks Equity Research
Nektar (NKTR) impresses with a strong pipeline of early and late-stage candidates. The company makes a significant progress with its lead candidate, Onzeald, for advanced breast cancer in adults.
Why is Nektar (NKTR) Stock Up More Than 350% This Year?
by Zacks Equity Research
Nektar's (NKTR) shares soar in the year so far on a robust pipeline including several study initiations and strategic collaborations.
Can Nektar Therapeutics (NKTR) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
Nektar Therapeutics (NKTR) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
Is the Options Market Predicting a Spike in Nektar (NKTR) Stock?
by Zacks Equity Research
Investors in Nektar (NKTR) need to pay close attention to the stock based on moves in the options market lately.
Nektar (NKTR) Stock Up More than 300% This Year: Here's Why
by Zacks Equity Research
Nektar's (NKTR) shares skyrocket in the year so far on a robust pipeline including several study initiations and strategic collaborations.
Company News For Nov 14, 2017
by Zacks Equity Research
Companies in the news are: TSN,JD,NKTR,GGP
Nektar/Bristol-Myers' Combo Trial Positive in Phase I/II
by Zacks Equity Research
Nektar (NKTR) and partner Bristol-Myers share positive interim data from dose-escalation part of a phase I/II study, evaluating NKTR-214 with Opdivo across three tumor types.
Nektar (NKTR) Q3 Earnings & Sales Surpass, Sales View Up
by Zacks Equity Research
Nektar's (NKTR) earnings and revenues beat estimates in Q3. The company also raises its revenue guidance for the same period.
Nektar Therapeutics (NKTR) Jumps: Stock Rises 10.54%
by Zacks Equity Research
Nektar Therapeutics (NKTR) was a big mover last session, as the company saw its shares nearly 11% on the day amid huge volumes.
Implied Volatility Surging for Nektar (NKTR) Stock Options
by Zacks Equity Research
Nektar (NKTR) needs investors to pay close attention to the stock based on moves in the options market lately.
Nektar's Lead Drugs Drive Growth, Partner Reliance a Woe
by Zacks Equity Research
Nektar (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.
Nektar (NKTR) Starts PROPEL Combo Study for Cancer Candidate
by Zacks Equity Research
Nektar (NKTR) initiates phase I/II combo study on lead candidate NKTR-214 along with Tecentriq and Keytruda. The trial complements Nektar's ongoing PIVOT research clubbed with Opdivo.
Surging Earnings Estimates Signal Good News for Nektar (NKTR)
by Zacks Equity Research
Nektar (NKTR) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
Are Options Traders Betting on a Big Move in Nektar (NKTR) Stock?
by Zacks Equity Research
Investors Nektar (NKTR) need to pay close attention to the stock based on moves in the options market lately.
Will Nektar's (NKTR) Candidates Enhance Growth in 2017?
by Zacks Equity Research
Nektar Therapeutics (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.
Nektar's (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag
by Zacks Equity Research
Nektar (NKTR) reports wider-than-expected loss with revenues falling shy of estimates. However, the top line rises year over year, courtesy an increase in product sales and royalty revenues.
Are Options Traders Betting on a Big Move in Nektar (NKTR) Stock?
by Zacks Equity Research
Investors in Nektar Therapeutics (NKTR) need to pay close attention to the stock based on moves in the options market lately.